http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-076523-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01cb38491dc4830d5ff33a930dc629a4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-317 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| filingDate | 2010-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bae678b750a0baee12f9f7d7fa4d5809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fb6d3a22bd4f9f44ea741c976be5a60 |
| publicationDate | 2011-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-076523-A1 |
| titleOfInvention | METHODS TO TREAT OR PREVENT OPHTHALMOLOGICAL DISEASES. COMPOSITION.COMPOSIT |
| abstract | Methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising the administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof. Claim 1: A method of treating or preventing an ophthalmologic disease, which comprises administration to a mammal in need of an effective amount of: (a) antagonist A or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, Fc KH902 VEGF receptor fusion protein, antibody 2C3, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG10X1, axicospan, PTG101, axospan , CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02 , peptide B3, TG100801, sorafenib or G6-31 antibody or a pharmaceutically acceptable salt thereof. Claim 6: The method according to claim 1, wherein the ophthalmologic disease is age-related macular degeneration, polypoid choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, neovascularization associated condition Peripheral retinal disease, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, iridesis rubeosis or a neoplasm. Claim 36: The method according to claim 1, wherein (a) or (b) are present in a drug delivery device. Claim 89: The method according to claim 2, wherein the compound of formula B is antagonist B or a pharmaceutically acceptable salt thereof. Claim 93: The method according to claim 3, wherein the compound of the formula C is the antagonist C or a pharmaceutically acceptable salt thereof. Claim 100: A composition comprising an effective amount of: (a) antagonist A, a compound of formula B, a compound of formula C, antagonist D, a compound of formula E or a pharmaceutically acceptable salt thereof; (b) ranibizumab, bevacizumab, aflibercept, Fc KH902 VEGF receptor fusion protein, antibody 2C3, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, axicospanide, PTKib1, axicospanide, PTZB1, axicospanide, PT-B1, axinibin CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, B3 peptide, TG100801, sorafenib or G6-31 antibody; and (c) a pharmaceutically acceptable carrier or vehicle. Claim 132: A compound of the formula E or a pharmaceutically acceptable salt thereof. Claim 133: A composition comprising: (a) an effective amount of a compound of the formula E or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle. Claim 135: The composition according to claim 133, wherein the compound is antagonist D. |
| priorityDate | 2009-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.